Garg A, Duggal L, Aggarwal S, Jain N
Department of Medicine, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi.
J Assoc Physicians India. 2006 Nov;54:883-6.
Patients with idiopathic hypereosinophilic syndrome (HES) show persistent hypereosinophilia of unknown etiology that is associated with end-organ damage. Different treatments, including the use of corticosteroids and cytotoxics, have been investigated for HES with modest success. We report a young patient with HES who developed stroke and remained refractory to conventional therapy. Therapy with imatinib mesylate, a selective tyrosine kinase inhibitor that is highly effective in treating patients with BCR-ABL-positive chronic myeloid leukemia, was tried with the patient. The result was impressive, with hematologic remission achieved rapidly. Our finding concurs with recent reports that imatinib mesylate may be a promising agent in the treatment of some cases of HES.
特发性嗜酸性粒细胞增多综合征（HES）患者表现出病因不明的持续性嗜酸性粒细胞增多，并伴有终末器官损害。针对HES，人们研究了包括使用皮质类固醇和细胞毒性药物在内的不同治疗方法，但取得的成效有限。我们报告了一名患有HES的年轻患者，该患者发生了中风，且对传统治疗无效。我们尝试对该患者使用甲磺酸伊马替尼进行治疗，甲磺酸伊马替尼是一种选择性酪氨酸激酶抑制剂，对治疗BCR-ABL阳性慢性髓性白血病患者非常有效。结果令人印象深刻，患者迅速实现了血液学缓解。我们的发现与最近的报告一致，即甲磺酸伊马替尼可能是治疗某些HES病例的有前景的药物。
